 Fulcrum Therapeutics NASDAQ:FULC has earned an average recommendation of Buy from the six research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report ... 